Filtered By:
Education: Academia
Procedure: Percutaneous Coronary Intervention
This page shows you your search results in order of date.
Order by Relevance | Date
Total 233 results found since Jan 2013.
De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy
CONCLUSIONS: In stabilised acute myocardial infarction patients, unguided de-escalation from ticagrelor to clopidogrel was associated with a lower rate of net adverse clinical outcomes irrespective of HBR status. The effect of de-escalation of P2Y12 inhibition on reducing haemorrhagic events was greater in patients with HBR.PMID:37724337 | DOI:10.4244/EIJ-D-23-00427
Source: EuroIntervention - September 19, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Min Chul Kim Sung Gyun Ahn Kyung Hoon Cho Doo Sun Sim Young Joon Hong Ju Han Kim Myung Ho Jeong Jun-Won Lee Young-Jin Youn Hee-Yeol Kim Ki-Dong Yoo Doo-Soo Jeon Eun-Seok Shin Young-Hoon Jeong Kiyuk Chang Youngkeun Ahn Source Type: research
Polypharmacy and Bleeding Outcomes After Percutaneous Coronary Intervention
CONCLUSIONS: In a real-world population of patients undergoing PCI, approximately 90% were on ≥5 medications. Increasing number of medications was associated with a higher adjusted risk for major bleeding, but not ischemic events.PMID:37722886 | DOI:10.1253/circj.CJ-23-0558
Source: Circulation Journal - September 18, 2023 Category: Cardiology Authors: Ko Yamamoto Takeshi Morimoto Masahiro Natsuaki Hiroki Shiomi Neiko Ozasa Hiroki Sakamoto Yasuaki Takeji Takenori Domei Takeshi Tada Ryoji Taniguchi Takashi Uegaito Miho Yamada Teruki Takeda Hiroshi Eizawa Satoru Suwa Manabu Shirotani Toshihiro Tamura Mori Source Type: research
The contribution  of genotype-guided selection of P2Y12 inhibitor on prognosis in ACS /CCS patients undergoing percutaneous coronary intervention: a retrospective cohort study
ConclusionsGenotype-guided selection of P2Y12 inhibitor made a very positive contribution on the prognosis in Chinese ACS/CCS patients undergoing PCI. Instead of intensifying antiplatelet strategies, conventional-dose clopidogrel could be recommended as P2Y12 inhibitor after weighing MACEs and bleeding events in CYP2C19 IM patients.
Source: European Journal of Clinical Pharmacology - July 14, 2023 Category: Drugs & Pharmacology Source Type: research
Usefulness of the PRECISE-DAPT score at differentiating between ticagrelor and prasugrel for dual antiplatelet therapy initiation
AbstractAs a part of dual antiplatelet therapy (DAPT), prasugrel or ticagrelor is prescribed along with aspirin to patients of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). We aimed to assess if the PRECISE-DAPT score, which provides prediction of bleeding during DAPT, could be used to choose between prasugrel and ticagrelor for DAPT initiation. 181 patients out of which 71 received prasugrel and 110 received ticagrelor were enrolled in this prospective cohort study. PRECISE-DAPT score was calculated for everyone and was used to dichotomize patients into two subgroups (score<25 and â...
Source: Journal of Thrombosis and Thrombolysis - July 4, 2023 Category: Hematology Source Type: research
The Combinations of the Patterns of Non-Adherence to Anti-Platelet Regimen in Stented Patients (PARIS) and Coronary Revascularization Demonstrating Outcome Study in Kyoto (CREDO-Kyoto) Thrombotic and Bleeding Risk Scores on Clinical Outcomes in Patients with Acute Myocardial Infarction
Conclusion The combinations of the PARIS and CREDO-Kyoto risk scores might be useful for evaluating ischemic and bleeding risks in patients with acute MI undergoing primary PCI.PMID:37344423 | DOI:10.2169/internalmedicine.2117-23
Source: Internal Medicine - June 21, 2023 Category: Internal Medicine Authors: Daichi Yamashita Yuichi Saito Takanori Sato Tadahiro Matsumoto Sakuramaru Suzuki Kan Saito Shinichi Wakabayashi Hideki Kitahara Koichi Sano Yoshio Kobayashi Source Type: research
P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial
EuroIntervention. 2023 Jun 12:EIJ-D-23-00125. doi: 10.4244/EIJ-D-23-00125. Online ahead of print.ABSTRACTDual antiplatelet therapy (DAPT) is currently the standard of care after percutaneous coronary intervention (PCI). Recent studies suggest that reducing DAPT to 1-3 months followed by an aspirin-free single antiplatelet therapy (SAPT) strategy with a potent P2Y12 inhibitor is safe and associated with less bleeding. However, to date, no randomised trial has tested the impact of initiating SAPT immediately after PCI, particularly in patients with acute coronary syndromes (ACS). NEOMINDSET is a multicentre, randomised, open...
Source: EuroIntervention - June 12, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Patricia O Guimar ães Marcelo Franken Caio A M Tavares Fabio S Silveira Murillo O Antunes Ricardo R Bergo Rodrigo M Joaquim Jessica C S Hirai Pedro B Andrade Fabio G Pitta Jos é Mariani Bruno R Nascimento Jo ão E T de Paula Marcos S Silveira Tiberio A Source Type: research
